Uniqure Nv Quote - 0EE0 | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
UK
LSE
Uniqure Nv (0EE0) Share Price

Uniqure Nv (0EE0)

31.50

0.00

(0.00%)

Closed 21 June 1:30AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

31.50

Bid

0.00

Offer

0.00

Volume

58

0.00 Day's Range 0.00

31.50 52 Week Range 31.50

Market Cap

Previous Close

31.50

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

736

Shares Outstanding

47,834,000

Dividend Yield

-

PE Ratio

-0.70

Earnings Per Share (EPS)

-6.45

Revenue

21.9M

Net Profit

-308.48M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.uniqure.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1970

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0EE0. The last closing price for Uniqure Nv was US$31.50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure Nv currently has 47,834,000 shares in issue. The market capitalisation of Uniqure Nv is US$215.25 million. Uniqure Nv has a price to earnings ratio (PE ratio) of -0.70.

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease ~ Designation based on 24-month interim Phase I/II...

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a...

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress ~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease;...

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease ~ Patients treated with AMT-130 continue to show evidence of preserved...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass...

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory...

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	31.5	31.5	31.5	3217	31.5	DE
4	0	0	31.5	31.5	31.5	1389	31.5	DE
12	0	0	31.5	31.5	31.5	736	31.5	DE
26	0	0	31.5	31.5	31.5	1219	31.5	DE
52	0	0	31.5	31.5	31.5	1361	31.5	DE
156	0	0	31.5	31.5	31.5	1188	31.5	DE
260	0	0	31.5	31.5	31.5	925	31.5	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TM1OTerra Metals Ltd	AUD 0.038 (245.45%)	2.9M
ME1OEMelodiol Global Health Ltd	AUD 0.003 (200.00%)	10.2k
TM1Terra Metals Ltd	AUD 0.073 (135.48%)	88.27M
JAVJavelin Minerals Ltd	AUD 0.002 (100.00%)	3.8M
D2OOADuxton Water Limited	AUD 0.04 (90.48%)	341
PR1OAPure Resources Ltd	AUD 0.004 (-50.00%)	50k
1CGOOne Click Group Ltd	AUD 0.002 (-50.00%)	490.53k
SGAOSarytogan Graphite Ltd	AUD 0.013 (-45.83%)	238.22k
BRXOABelararox Ltd	AUD 0.013 (-40.91%)	264.14k
CYPOACynata Therapeutics Ltd	AUD 0.055 (-38.89%)	62.4k
TM1Terra Metals Ltd	AUD 0.073 (135.48%)	88.27M
REDRed 5 Limited	AUD 0.405 (-9.50%)	82.44M
BTRBrightstar Resources Limited	AUD 0.018 (24.14%)	67.68M
TLSTelstra Corporation Limited	AUD 3.61 (0.84%)	36.03M
BFCBeston Global Food Company Limited	AUD 0.003 (0.00%)	31.73M

Roofus

Roofus 2 minutes ago

Bold prediction :-)

richrob47

richrob47 2 minutes ago

Some activity today...

bubba412

bubba412 3 minutes ago

Please show me my scary tactics or post that are un true

brooklyn13

brooklyn13 3 minutes ago

No, you're a moron because you're stupid.

Yowzah, boss, we's gonna keep making them good bagels.

getmoreshares

getmoreshares 3 minutes ago

the bidder at 79- switched an slapped 80

Smitty5150

Smitty5150 3 minutes ago

What happened to the "doxxing" lawsuit you threatened to file when you were exposed for manipulating another small biotech in a lawsuit filed by said Company in Florida? My bet is your legal counsel laughed, just like I did, when you falsely claimed you were being doxxed. You had zero grounds to sta

HippyTrades

HippyTrades 3 minutes ago

Yikes.
Get out while you can.

sawxman

sawxman 3 minutes ago

Setting up for another classic performance

DimesForShares

DimesForShares 3 minutes ago

Want2retire: “Once quality consistent mass production is proven, deliveries are made, revenues are received, additional contracts are signed, military funding is secured, etc, what would you value the company at on a price per share basis?”

There is simply no way to answer this questi

Number sleven

Number sleven 3 minutes ago

https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/nlrp3-and-sasp-in-vazkepa-therapy-in-cvd-patients-with-or-without-t2dm/
Don't know if this has been posted.
Sleven,

syncmaster175v

syncmaster175v 3 minutes ago

Yes thank you so much

chemist72

chemist72 3 minutes ago

JPEX up 200% today. Weeeee! LOL

Birch69696969

Birch69696969 4 minutes ago

A new 52 low at .0009.

Juststoppingby

Juststoppingby 4 minutes ago

Maybe because of Market Maker GTSM's big overseas exposure? There were after-hour trades on Tuesday.

WALLnut

WALLnut 4 minutes ago

I predict they'll submit IDE in the next 196 hours. 😎

Rdgl

NeutrinoKid

NeutrinoKid 4 minutes ago

Could you make a plant grow faster if you pull on it? I think that this is a very good question.

Invest-in-America

Invest-in-America 4 minutes ago

GRDI: Maybe their Warrants a better play, right now????? (Who cares.)

nowwhat2

nowwhat2 5 minutes ago

Crucial Juncture.....and what occurs ?

BITCOIN ;https://investorshub.advfn.com/uimage/uploads/2024/6/18/kdemnBTC_666_18_1Y_630PM_ON_TL_CRUCIAL_JUNCTURE.jpg

An IHub "Glitch" Develops ! .......We are handed this page here instead of The Charts Page :

Zorax

Zorax 5 minutes ago

I don't prescribe to your agenda so I'm a moron?

I don't bend to your will, so I'm a maga?

I don't rightly care what you think or spew, but keep making those REAL bagels please, the phony soft kind suck.
New York bagel is the best.

Jack_Bolander

Jack_Bolander 5 minutes ago

Studer - Yes. Just like MULAG !

fink

fink 5 minutes ago

Thanks for the shares.

Guess a little attention was enough of a push for retail to be reminded of how long they've been stuck in here.

I can't see bailing now.

VeronicaFox

VeronicaFox 5 minutes ago

100% agreed.

https://investorshub.advfn.com/uimage/uploads/2024/6/20/ezergIMG_2605.jpeg

Hoghead7

Hoghead7 5 minutes ago

I am finally getting a nice commission tomorrow and it seems as though timing couldn't be more perfect. It would be a dream to pick up shares under $0.75 and watch it go to $2 by the September conference call. We need an interpreter on those 45 v rules I posted a little while ago. I believe that'

The Man With No Name

The Man With No Name 6 minutes ago

zero basis…

Do you mean like the notion that Treasury, after all their self-serving, will find it in their hearts to give common shareholders a gift? How much do you think they are more likely to give, 50 million or 50 billion?

The 'basis' is priority of payment.

Inter Rao Lietuva Ab

Invesco Goldman Sachs Eq...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions